Angiogenesis in cancer and other diseases
The DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Pathological angiogenesis is a hallmark of cancer and various ischaemic and inflammatory diseases. Concentrated efforts in this area of research are leading to the discovery of a growing number of pro- and anti-angiogenic molecules, some of which are already in clinical trials. The complex interactions among these molecules and how they affect vascular structure and function in different environments are now beginning to be elucidated. This integrated understanding is leading to the development of a number of exciting and bold approaches to treat cancer and other diseases. But owing to several unanswered questions, caution is needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of vascularization is one of the landmarks of tumor environments [57,180].”
From The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors (2019) · cites this paper as [180]
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“This hypothesis formed the basis of the discovery of angiostatin, endostatin, vasculostatin and other endogenous inhibitors of angiogenesi”
BackgroundMechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,162 · cited 1×
“We now know there are various molecular players involved in these different mechanisms of vascular growt”
BackgroundSelf-citationAbnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Self-citationO'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345 · cited 1×
“This hypothesis formed the basis of the discovery of angiostatin, endostatin, vasculostatin and other endogenous inhibitors of angiogenesi”
BackgroundRole of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502 · cited 1×
“However, caution is warranted as these hypoxia-inducible factors could also control cell deat”
BackgroundSelf-citationRegulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Self-citationCancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model
Arap, W., Pasqualini, R., & Ruoslahti, E. (1998) · Science · doi:10.1126/science.279.5349.377 · Cited by 2,054 · cited 1×
“In vivo selection of phage display libraries has recently yielded peptides (for example, amino-acid sequences RGD and NGR) that preferentially recognize vessels in subcutaneous tumours in mic”
BackgroundOpenings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Self-citationHelmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628
Self-citation
Research works printed but not linked: 8
- Greenblatt, M. & Shubik, P. Tumor angiogenesis: transfilter diffusion studies in the hamster by the transparant chamber technique. J. Natl Cancer Inst. 41, 111–124 (1968).
- Ehrmann, R. L. & Knoth, M. Choriocarcinoma: transfilter stimulation of vasoproliferation in the hamster cheek pouch studied by light and electron microscopy. J. Natl Cancer Inst. 41, 1329 –1341 (1968).
- Folkman, J. in Cancer Medicine (eds Holland, J. F. et al.) 132– 152 (Decker, Ontario, Canada, 2000).
- Chang, Y. S. et al. Abundance of neoplastic cells in vessel walls of human tumor xenografts. Proc. Am. Assoc. Cancer Res. (in the press).
- Seljelid, R., Jozefowski, S. & Sveinbjornsson, B. Tumor stroma. Anticancer Res. 19, 4809–4822 (1999).
- Buschmann, I. & Schaper, W. The pathophysiology of the collateral circulation (arteriogenesis). J. Pathol. 190, 338–342 (2000). · doi:10.1002/(sici)1096-9896(200002)190:3<338::aid-path594>3.0.co;2-7
- Carmeliet, P. & Collen, D. Transgenic mouse models in angiogenesis and cardiovascular disease. J. Pathol. 190, 387–405 (2000). · doi:10.1002/(sici)1096-9896(200002)190:3<387::aid-path595>3.0.co;2-r
- Tsuzuki, Y. et al. VEGF modulation by targeting HIF-1alpha/HRE/VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res. (in the press).
Cited by
Items 701–800 of 1,084
Enhancing Radiotherapy With Cyclooxygenase-2 Enzyme Inhibitors: A Rational Advance?
Choy, H. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg058 · Cited by 191
Thibault, B., Castells, M., Delord, J.-P., & Couderc, B. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9456-2 · Cited by 184
“The arrival of new vessels is a rate-limiting step of tumor development as when the diameter of a tumor becomes greater than 100–200 μm, the diffusion of nutrients and oxygen is not sufficient to reach all cells [115] (for review see [116]).”
BackgroundYan, H., Wang, L., Wang, J., Weng, X., Lei, H., Wang, X., Jiang, L., Zhu, J., Lu, W., Wei, X., et al. (2012) · ACS Nano · doi:10.1021/nn203749v · Cited by 191
Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma
Huang, S.-P., Wu, M.-S., Shun, C.-T., Wang, H.-P., Lin, M.-T., Kuo, M.-L., & Lin, J.-T. (2004) · Journal of Biomedical Science · doi:10.1007/bf02256101 · Cited by 190
Cell proliferation drives neural crest cell invasion of the intestine
Simpson, M. J., Zhang, D. C., Mariani, M., Landman, K. A., & Newgreen, D. F. (2007) · Developmental Biology · doi:10.1016/j.ydbio.2006.10.017 · Cited by 190
“Invasion processes are central to pathological events such as tumor-derived angiogenesis, whereby cancers attract a vascular network (Folkman and Haudenschild, 1980; Carmellet and Jaln, 2000).”
BackgroundPark, J. H., Kwon, S., Nam, J.-O., Park, R.-W., Chung, H., Seo, S. B., Kim, I.-S., Kwon, I. C., & Jeong, S. Y. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2003.12.020 · Cited by 190
Sequential assembly of cell‐laden hydrogel constructs to engineer vascular‐like microchannels
Du, Y., Ghodousi, M., Qi, H., Haas, N., Xiao, W., & Khademhosseini, A. (2011) · Biotechnology and Bioengineering · doi:10.1002/bit.23102 · Cited by 190
Nonlinear simulation of the effect of microenvironment on tumor growth
Macklin, P., & Lowengrub, J. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2006.12.004 · Cited by 191
“…in response to the imbalance of pro-angiogenic growth factors that are released by hypoxic cells in the tumor (e.g., vascular endothelial cell growth factor, or VEGF) relative to anti-angiogenic growth factors (e.g., angiostatin) present in the tumor microenvironment (Carmellet and Jain, 2000).”
BackgroundDai, Y., Hartandi, K., Ji, Z., Ahmed, A. A., Albert, D. H., Bauch, J. L., Bouska, J. J., Bousquet, P. F., Cunha, G. A., Glaser, K. B., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061280h · Cited by 187
Intratumoral Drug Delivery with Nanoparticulate Carriers
Holback, H., & Yeo, Y. (2011) · Pharmaceutical Research · doi:10.1007/s11095-010-0360-y · Cited by 187
Ewan, L. C., Jopling, H. M., Jia, H., Mittar, S., Bagherzadeh, A., Howell, G. J., Walker, J. H., Zachary, I. C., & Ponnambalam, S. (2006) · Traffic · doi:10.1111/j.1600-0854.2006.00462.x · Cited by 183
“Phosphorylation of VEGFR2 mediates plasma membrane recruitment and tyrosine phosphorylation of phospholipase Cg1 leading to phosphoinositide breakdown and generation of inositol (1,4,5)-triphosphate and diacylglycerol (9,10).”
BackgroundDissection of angiogenic signaling in zebrafish using a chemical genetic approach
Chan, J., Bayliss, P. E., Wood, J. M., & Roberts, T. M. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00042-9 · Cited by 190
“However, inverte- growth (reviewed in Carmeliet and Jain, 2000).”
Kunz-Schughart, L. A., Schroeder, J. A., Wondrak, M., van Rey, F., Lehle, K., Hofstaedter, F., & Wheatley, D. N. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00248.2005 · Cited by 184
“In the interim, a number of angiogenic and angiostatic mediators have been identified, and inhibition of angiogenesis is now a therapeutic strategy implemented for patients with rheumatoid arthritis, cancer, and hypertrophic scarring (4, 11, 17, 41, 50), whereas systemic sclerosis as a fibrotic disease with a reduced…”
MMP‐2 and MMP‐9 synergize in promoting choroidal neovascularization
Lambert, V., Wielockx, B., Munaut, C., Galopin, C., Jost, M., Itoh, T., Werb, Z., Baker, A., Libert, C., Krell, H.-W., et al. (2003) · The FASEB Journal · doi:10.1096/fj.03-0113fje · Cited by 189
“The net balance between positive and negative regulatory molecules controls angiogenesis (4).”
BackgroundDetection and isolation of circulating tumor cells: Principles and methods
Esmaeilsabzali, H., Beischlag, T. V., Cox, M. E., Parameswaran, A. M., & Park, E. J. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.08.016 · Cited by 189
Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells
Aikawa, T., Whipple, C. A., Lopez, M. E., Gunn, J., Young, A., Lander, A. D., & Korc, M. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32412 · Cited by 189
Potential Role for ADAM15 in Pathological Neovascularization in Mice
Horiuchi, K., Weskamp, G., Lum, L., Hammes, H.-P., Cai, H., Brodie, T. A., Ludwig, T., Chiusaroli, R., Baron, R., Preissner, K. T., et al. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.16.5614-5624.2003 · Cited by 189
“Tumors must recruit host vessels for survival (10); hence, tumor angiogenesis is a critical factor for tumor growth.”
BackgroundChoi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
“Consequently, the vasculature that forms within tumors is heterogeneous and poorly perfused, comprising abnormal and leaky blood vessels 17,19,20 .”
BackgroundDirectly coaxial 3D bioprinting of large-scale vascularized tissue constructs
Shao, L., Gao, Q., Xie, C., Fu, J., Xiang, M., & He, Y. (2020) · Biofabrication · doi:10.1088/1758-5090/ab7e76 · Cited by 188
Extravasation of polymeric nanomedicines across tumor vasculature
Danquah, M. K., Zhang, X. A., & Mahato, R. I. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.11.005 · Cited by 188
Angiogenesis: vascular remodeling of the extracellular matrix involves metalloproteinases
Heissig, B., Hattori, K., Friedrich, M., Rafii, S., & Werb, Z. (2003) · Current Opinion in Hematology · doi:10.1097/00062752-200303000-00007 · Cited by 188
VEGF blockade inhibits angiogenesis and reepithelialization of endometrium
Fan, X., Krieg, S., Kuo, C. J., Wiegand, S. J., Rabinovitch, M., Druzin, M. L., Brenner, R. M., Giudice, L. C., & Nayak, N. R. (2008) · The FASEB Journal · doi:10.1096/fj.08-111401 · Cited by 188
“During the past 2 decades, enormous progress has been made in understanding the mechanism of angiogenesis in different pathophysiological conditions, and antiangiogenic therapy is emerging as a major treatment modality of various cancers (4 – 6). Vascular endothelial growth factor (VEGF) is known to be required for no…”
BackgroundLi, N., Cai, H., Jiang, L., Hu, J., Bains, A., Hu, J., Gong, Q., Luo, K., & Gu, Z. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b15505 · Cited by 188
Ekstrand, A. J., Cao, R., Björndahl, M., Nyström, S., Jönsson-Rylander, A.-C., Hassani, H., Hallberg, B., Nordlander, M., & Cao, Y. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1135965100 · Cited by 188
Kashiwagi, S., Izumi, Y., Gohongi, T., Demou, Z. N., Xu, L., Huang, P. L., Buerk, D. G., Munn, L. L., Jain, R. K., & Fukumura, D. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24015 · Cited by 188
Self-citationChaudhry, I. H., O'Donovan, D. G., Brenchley, P. E. C., Reid, H., & Roberts, I. S. D. (2001) · Histopathology · doi:10.1046/j.1365-2559.2001.01230.x · Cited by 188
Cuneo, K. C., Vredenburgh, J. J., Sampson, J. H., Reardon, D. A., Desjardins, A., Peters, K. B., Friedman, H. S., Willett, C. G., & Kirkpatrick, J. P. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.12.074 · Cited by 185
MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth
Zhou, B., Ma, R., Si, W., Li, S., Xu, Y., Tu, X., & Wang, Q. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.028 · Cited by 188
“Angiogenesis is a balanced process that is delicately regulated by many molecules, including some activators and some inhibitors [2].”
BackgroundMechanisms of resistance to antiangiogenesis therapy
Azam, F., Mehta, S., & Harris, A. L. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.020 · Cited by 178
Piezo1 mediates angiogenesis through activation of MT1-MMP signaling
Kang, H., Hong, Z., Zhong, M., Klomp, J., Bayless, K. J., Mehta, D., Karginov, A. V., Hu, G., & Malik, A. B. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00346.2018 · Cited by 183
“Angiogenesis, the formation of new capillaries from preexisting vessels, is an essential feature of embryonic development, inflammation, wound healing, tissue repair, and tumor growth (3).”
BackgroundMedicinal Benefits of Green Tea: Part II. Review of Anticancer Properties
Cooper, R., Morré, D. J., & Morré, D. M. (2005) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2005.11.639 · Cited by 187
“86 In the healthy human adult, the endothelium is generally quiescent, and turnover of endothelial cells is extremely slow.”
Rajagopalan, S., Olin, J., Deitcher, S., Pieczek, A., Laird, J., Grossman, P. M., Goldman, C. K., McEllin, K., Kelly, R., & Chronos, N. (2007) · Circulation · doi:10.1161/circulationaha.106.607994 · Cited by 187
Angiopoietin: A TIE(d) Balance in Tumor Angiogenesis
Shim, W. S. N., Ho, I. A. W., & Wong, P. E. H. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0072 · Cited by 187
“Malignant cells transverse such limitations by accumulating mutations that stoke angiogenic response or by sequestrating circulating growth inhibitors (2).”
Zhang, L., Athale, C. A., & Deisboeck, T. S. (2007) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2006.06.034 · Cited by 187
“Based on the experimentally determined diffusion distance of oxygen in tissue, we have limited it to a (rescaled) 100 mm distance from the location of the blood vessel (Carmeliet and Jain, 2000).”
BackgroundInfluentialSingh, R. P., Tyagi, A. K., Dhanalakshmi, S., Agarwal, R., & Agarwal, C. (2004) · International Journal of Cancer · doi:10.1002/ijc.11620 · Cited by 184
Sun, Y., & Davis, E. (2021) · Nanomaterials · doi:10.3390/nano11030746 · Cited by 165
Guenzi, E. (2001) · The EMBO Journal · doi:10.1093/emboj/20.20.5568 · Cited by 188
Pepper, M. S., & Skobe, M. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200308082 · Cited by 184
“Tumor cells are believed to be passively carried into the lymphatic vessels with the interstitial fluid and proteins (Hartveit, 1990), and the prevailing view has been that lymphangiogenesis is not a part of tumorigenesis (Carmeliet and Jain, 2000; Leu et al., 2000; Padera et al., 2002).”
HIFs and tumors—causes and consequences
Höpfl, G., Ogunshola, O., & Gassmann, M. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00538.2003 · Cited by 185
“The idea of having an avascular tumor mass depending on neoangiogenesis (and therefore on angiogenic factors such as VEGF to allow the tumor’s growth) brought about a concept called the “angiogenic switch” (33, 73, 84, 209).”
BackgroundXiao, X., Wang, W., Liu, D., Zhang, H., Gao, P., Geng, L., Yuan, Y., Lu, J., & Wang, Z. (2015) · Scientific Reports · doi:10.1038/srep09409 · Cited by 185
Giavazzi, R., Sennino, B., Coltrini, D., Garofalo, A., Dossi, R., Ronca, R., Tosatti, M. P. M., & Presta, M. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64325-8 · Cited by 185
Trujillo-de Santiago, G., Flores-Garza, B. G., Tavares-Negrete, J. A., Lara-Mayorga, I. M., González-Gamboa, I., Zhang, Y. S., Rojas-Martínez, A., Ortiz-López, R., & Álvarez, M. M. (2019) · Materials · doi:10.3390/ma12182945 · Cited by 184
“Therefore, vascularization is another relevant aspect to consider when engineering a tumor local microenvironment [180,181].”
BackgroundThe genetic and epigenetic alterations in human hepatocellular carcinoma: a recent update
Liu, M., Jiang, L., & Guan, X.-Y. (2014) · Protein & Cell · doi:10.1007/s13238-014-0065-9 · Cited by 184
“Formation of tumor vessels can accelerate the proliferation, growth, and metastasis of cancer cells (Carmeliet and Jain, 2000).”
BackgroundCyclooxygenase-2 in Endometriosis
Lai, Z.-Z., Yang, H.-L., Ha, S.-Y., Chang, K.-K., Mei, J., Zhou, W.-J., Qiu, X.-M., Wang, X.-Q., Zhu, R., Li, D.-J., et al. (2019) · International Journal of Biological Sciences · doi:10.7150/ijbs.35128 · Cited by 162
“The development of the ectopic endometrium relies on angiogenesis, which is a characterizing factor of EMS [48].”
BackgroundTargeting the tumour vasculature: from vessel destruction to promotion
Guelfi, S., Hodivala-Dilke, K., & Bergers, G. (2024) · Nature Reviews Cancer · doi:10.1038/s41568-024-00736-0 · Cited by 183
Ji, T., Zhao, Y., Ding, Y., & Nie, G. (2013) · Advanced Materials · doi:10.1002/adma.201300299 · Cited by 183
The Biochemical and Functional Food Properties of the Bowman-Birk Inhibitor
Losso, J. N. (2008) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408390601177589 · Cited by 183
Lymphatic function, lymphangiogenesis, and cancer metastasis
Swartz, M. A., & Skobe, M. (2001) · Microscopy Research and Technique · doi:10.1002/jemt.1160 · Cited by 183
Novel anti(lymph)angiogenic treatment strategies for corneal and ocular surface diseases
Bock, F., Maruyama, K., Regenfuss, B., Hos, D., Steven, P., Heindl, L. M., & Cursiefen, C. (2013) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2013.01.001 · Cited by 183
Lamy, S., Lachambre, M.-P., Lord-Dufour, S., & Béliveau, R. (2010) · Vascular Pharmacology · doi:10.1016/j.vph.2010.08.002 · Cited by 178
“Angiogenesis, the process of new blood vessel growth from preexisting capillaries, is essential for embryogenesis, functioning of the female reproductive system, and wound healing (Carmeliet and Jain, 2000).”
BackgroundQureshi-Baig, K., Kuhn, D., Viry, E., Pozdeev, V. I., Schmitz, M., Rodriguez, F., Ullmann, P., Koncina, E., Nurmik, M., Frasquilho, S., et al. (2020) · Autophagy · doi:10.1080/15548627.2019.1687213 · Cited by 177
“This is, in part, explained by the fact that hypoxia is the major driving force behind tumor vascularization and invasion [33,34].”
BackgroundRobinson, C. J., Mulloy, B., Gallagher, J. T., & Stringer, S. E. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m510760200 · Cited by 175
The Metabolic Mechanisms of Breast Cancer Metastasis
Wang, L., Zhang, S., & Wang, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.602416 · Cited by 182
“And the intratumoral blood vessels characterized by increased permeability allow cancer cells to enter the systemic circulation readily (85).”
BackgroundEndostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications
Walia, A., Yang, J. F., Huang, Y.-H., Rosenblatt, M. I., Chang, J.-H., & Azar, D. T. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.09.007 · Cited by 182
“Soon after the discovery of endostatin’s critical role in inhibiting angiogenesis, the pharmaceutical development of endostatin became the focus of much research [229].”
Fricke, I., Mirza, N., Dupont, J., Lockhart, C., Jackson, A., Lee, J.-H., Sosman, J. A., & Gabrilovich, D. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0409 · Cited by 182
“VEGF is critically important for neovascularization and hematopoiesis during embryogenesis (2, 3).”
BackgroundProtein kinase C inhibitors as novel anticancer drugs
Jirousek, M. R., & Goekjian, P. G. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2117 · Cited by 182
Chemokines: novel targets for breast cancer metastasis
Ali, S., & Lazennec, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9073-z · Cited by 180
“The ECM surrounding ductal carcinoma cells contains active cells, including fibroblasts and TAMs [98, 99].”
CT Perfusion in Oncologic Imaging: A Useful Tool?
García-Figueiras, R., Goh, V. J., Padhani, A. R., Baleato-González, S., Garrido, M., León, L., & Gómez-Caamaño, A. (2013) · American Journal of Roentgenology · doi:10.2214/ajr.11.8476 · Cited by 175
“© American Roentgen Ray Society T umor-related angiogenesis is a complex process involving the growth of new blood vessels by cooption of neighboring vessels, sprouting or intussusceptive microvascular growth, and vasculogenesis from endothelial precursor cells [1].”
BackgroundBui, B. P., Nguyen, P. L., Lee, K., & Cho, J. (2022) · Cancers · doi:10.3390/cancers14246054 · Cited by 194
“The sustained expansion of a tumor mass requires new blood vessel formation to rapidly provide proliferative tumor cells with a sufficient supply of oxygen and nutrients [57].”
BackgroundKachgal, S., & Putnam, A. J. (2011) · Angiogenesis · doi:10.1007/s10456-010-9194-9 · Cited by 175
Role of copper in tumour angiogenesis—clinical implications
Nasulewicz, A., Mazur, A., & Opolski, A. (2004) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2004.02.004 · Cited by 180
Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation
Schmid, M. C., & Varner, J. A. (2010) · Journal of Oncology · doi:10.1155/2010/201026 · Cited by 180
“Specific growth factors, such as vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), stimulate the proliferation and migration of naturally quiescent endothelial cells, resulting in the formation of new vessel structures during embryonic development and tumor growth [7].”
BackgroundImmunotherapy of Cancer with 4-1BB
Vinay, D. S., & Kwon, B. S. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0677 · Cited by 180
“Pathological angiogenesis is an important aspect of cancers (43).”
BackgroundBos, R., Van Diest, P. J., De Jong, J. S., Van Der Groep, P., Van Der Valk, P., & Van Der Wall, E. (2005) · Histopathology · doi:10.1111/j.1365-2559.2005.02045.x · Cited by 180
“In cancer, PDGF and its receptors stimulate microvascular sprouting by attracting pericytes and smooth muscle cells during angiogenesis.(12) The growth inhibiting factors, transforming growth factor (TGF)-b1 and TGF-b2 are homodimers that bind their receptor couple TGF-bR-I and TGF-bR-II.”
BackgroundAngiogenesis modulation in cancer research: novel clinical approaches
Cristofanilli, M., Charnsangavej, C., & Hortobagyi, G. N. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd819 · Cited by 179
Cancer spread and micrometastasis development: Quantitative approaches for in vivo models
MacDonald, I. C., Groom, A. C., & Chambers, A. F. (2002) · BioEssays · doi:10.1002/bies.10156 · Cited by 181
“Although transillumination in elegant models such as ear or dorsal skinfold windows((53)) provides excellent stabilized views of cells within the microvasculature or vessels within tumors, many of the observations apply to a wound healing situation rather than arrest of cells in otherwise healthy tissue.”
BackgroundAngiogenesis and Blood-Brain Barrier Permeability in Vascular Remodeling after Stroke
Yang, Y., & Torbey, M. T. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200720173316 · Cited by 179
“Cerebral ischemia-induced angiogenesis is a complex and dynamic process involving the different vascular components such as ECs, vascular ACs and PCs, fibroblasts, smooth muscle cells, and the extracellular matrix [120-122].”
BackgroundFunction of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors
Sund, M., Hamano, Y., Sugimoto, H., Sudhakar, A., Soubasakos, M., Yerramalla, U., Benjamin, L. E., Lawler, J., Kieran, M., Shah, A., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500180102 · Cited by 179
Emerging tumor spheroids technologies for 3D in vitro cancer modeling
Rodrigues, T., Kundu, B., Silva-Correia, J., Kundu, S. C., Oliveira, J. M., Reis, R. L., & Correlo, V. M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.018 · Cited by 178
Nguyen, D. D., & Lai, J.-Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.134970 · Cited by 178
Vascular Endothelial Cells: Heterogeneity and Targeting Approaches
Hennigs, J. K., Matuszcak, C., Trepel, M., & Körbelin, J. (2021) · Cells · doi:10.3390/cells10102712 · Cited by 178
“However, in tumor tissue, the expression of VEGF and a number of anti-angiogenic factors is uncoordinated and out of balance [28].”
BackgroundMicroparticles in Angiogenesis: Therapeutic Potential
Martinez, M. C., & Andriantsitohaina, R. (2011) · Circulation Research · doi:10.1161/circresaha.110.233049 · Cited by 178
Carlsson, L., Clarke, J. C., Yen, C., Gregoire, F., Albery, T., Billger, M., Egnell, A.-C., Gan, L.-M., Jennbacken, K., Johansson, E., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.04.003 · Cited by 178
Analysis of Mural Cell Recruitment to Tumor Vessels
Abramsson, A., Berlin, O., Papayan, H., Paulin, D., Shani, M., & Betsholtz, C. (2002) · Circulation · doi:10.1161/hc0102.101437 · Cited by 178
Cross‐talk between the VEGF‐A and HGF signalling pathways in endothelial cells
Sulpice, E., Ding, S., Muscatelli‐Groux, B., Bergé, M., Han, Z. C., Plouet, J., Tobelem, G., & Merkulova‐Rainon, T. (2009) · Biology of the Cell · doi:10.1042/bc20080221 · Cited by 178
“Angiogenesis is regulated by a number of hormones, cytokines, growth factors and low-molecularmass mediators (Carmeliet and Jain, 2000).”
BackgroundVascular Endothelial Growth Factor-A Promotes Peritumoral Lymphangiogenesis and Lymphatic Metastasis
Björndahl, M. A., Cao, R., Burton, J. B., Brakenhielm, E., Religa, P., Galter, D., Wu, L., & Cao, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2345 · Cited by 178
Nishiwada, S., Sho, M., Yasuda, S., Shimada, K., Yamato, I., Akahori, T., Kinoshita, S., Nagai, M., Konishi, N., & Nakajima, Y. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0144-7 · Cited by 172
“And VEGF is the dominant angiogenic factor in the tumor microenvironment [35,36].”
BackgroundExosomes and extracellular vesicles: Rethinking the essential values in cancer biology
Yokoi, A., & Ochiya, T. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.032 · Cited by 167
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
König, Y., Bock, F., Horn, F. K., Kruse, F. E., Straub, K., & Cursiefen, C. (2009) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1099-1 · Cited by 177
“neovascularization [ 4 , 5]. Bevacizumab (Avastin, Roche Pharma AG) is a humanized monoclonal antibody blocking VEGF-A, which results in inhibition of the outgrowth of new vessels.”
BackgroundOptical spectroscopy for detection of neoplasia
Sokolov, K., Follen, M. M., & Richards-Kortum, R. R. (2002) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(02)00381-2 · Cited by 177
Silibinin Inhibits Colorectal Cancer Growth by Inhibiting Tumor Cell Proliferation and Angiogenesis
Singh, R. P., Gu, M., & Agarwal, R. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6247 · Cited by 177
“to support the growth of solid tumors beyond a critical size and provide a viable route for tumor metastasis to distant organs (10).”
BackgroundNanodelivery Strategies in Cancer Chemotherapy: Biological Rationale and Pharmaceutical Perspectives
Mattheolabakis, G., Rigas, B., & Constantinides, P. P. (2012) · Nanomedicine · doi:10.2217/nnm.12.128 · Cited by 177
Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu
Rattigan, Y., Hsu, J.-M., Mishra, P. J., Glod, J., & Banerjee, D. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.07.002 · Cited by 176
Engineering Tumors: A Tissue Engineering Perspective in Cancer Biology
Burdett, E., Kasper, F. K., Mikos, A. G., & Ludwig, J. A. (2010) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2009.0676 · Cited by 172
“93,94 97”
A critical role of placental growth factor in the induction of inflammation and edema formation
Oura, H., Bertoncini, J., Velasco, P., Brown, L. F., Carmeliet, P., & Detmar, M. (2003) · Blood · doi:10.1182/blood-2002-05-1516 · Cited by 176
Self-citationEffect of statin therapy on colorectal cancer
Bardou, M., Barkun, A., & Martel, M. (2010) · Gut · doi:10.1136/gut.2009.190900 · Cited by 175
“Inhibition of angiogenesis Angiogenesis is indispensable for the growth of solid tumours, and without the supply of new blood vessels, the size of a tumour can only reach a volume of about 2 mm(3).(51) It has been suggested Figure 2 Suggested effect of statin on mitochondria-mediated apoptotic signalling.”
BackgroundRegulation and Action of Angiogenic Factors in the Primate Ovary
Stouffer, R. L., Martı́nez-Chequer, J. C., Molskness, T. A., Xu, F., & Hazzard, T. M. (2001) · Archives of Medical Research · doi:10.1016/s0188-4409(01)00323-x · Cited by 175
Synthetic and Bone tissue engineering graft substitutes: What is the future?
Valtanen, R. S., Yang, Y. P., Gurtner, G. C., Maloney, W. J., & Lowenberg, D. W. (2021) · Injury · doi:10.1016/j.injury.2020.07.040 · Cited by 158
Wu, W.-S., Wang, F.-S., Yang, K. D., Huang, C.-C., & Kuo, Y.-R. (2006) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700274 · Cited by 174
“, 1999; Carmeliet and Jain, 2000). The most abundant of the four VEGF isoforms, VEGF-A, is typically utilized in biological angiogenic studies (Ferrara et al., 1992; Thomas, 1996). Recently, Gira et al. (2004) indicated that VEGF production is abundant in the underlying dermis of keloids.”
BackgroundInterleukin-10 Ablation Promotes Tumor Development, Growth, and Metastasis
Tanikawa, T., Wilke, C. M., Kryczek, I., Chen, G. Y., Kao, J., Núñez, G., & Zou, W. (2012) · Cancer Research · doi:10.1158/0008-5472.can-10-4627 · Cited by 174
“However, it is also possible that the reduced density of tumormicrovesselsmay be due to the resulting enhanced T-cell immunity that includes the production of IFNg , a potent antiangiogenic factor (46).”
Lee, S. H., Lopes de Menezes, D., Vora, J., Harris, A., Ye, H., Nordahl, L., Garrett, E., Samara, E., Aukerman, S. L., Gelb, A. B., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2129 · Cited by 174
EWS–ETS oncoproteins: The linchpins of Ewing tumors
Janknecht, R. (2005) · Gene · doi:10.1016/j.gene.2005.08.007 · Cited by 173
Advances in On-Chip Vascularization
Haase, K., & Kamm, R. D. (2017) · Regenerative Medicine · doi:10.2217/rme-2016-0152 · Cited by 173
Regenerative Approaches for the Treatment of Large Bone Defects
Stahl, A., & Yang, Y. P. (2021) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2020.0281 · Cited by 173
“87 TE constructs need to either include a vascular system capable of being connected to the host system for immediate reperfusion like the vascularized fibular graft or else promote rapid revascularization in situ to ensure graft survival and tissue repair.”
Regulation of hypoxia-induced angiogenesis: a chaperone escorts VEGF to the dance
Semenza, G. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13374 · Cited by 173
Kaur, B., Brat, D. J., Devi, N. S., & Van Meir, E. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208317 · Cited by 173
“…better understanding of the mechanisms that activate angiostatic factors that normally suppress unregulated vascular growth in normal tissues is needed and could be exploited for the development of novel therapeutics for cancer and other diseases of aberrant angiogenesis (Carmeliet and Jain, 2000).”
BackgroundBevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Desjardins, A., Reardon, D. A., Herndon, J. E., Marcello, J., Quinn, J. A., Rich, J. N., Sathornsumetee, S., Gururangan, S., Sampson, J., Bailey, L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0260 · Cited by 173
Roles of Thrombospondin-1 and -2 in Regulating Corneal and Iris Angiogenesis
Cursiefen, C., Masli, S., Ng, T. F., Dana, M. R., Bornstein, P., Lawler, J., & Streilein, J. W. (2004) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.03-0940 · Cited by 173
“Recent interest has focused on these natural inhibitors of angiogenesis, because they may be of therapeutic use in diseases leading to CNV and subsequent blindness.(21,24) Previous reports on the effects on developmental and postnatal angiogenesis of a deficit of a single antiangiogenic factor did not reveal spontaneo…”
BackgroundKudo, M., Aoki, T., Ueshima, K., Tsuchiya, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2023) · Liver Cancer · doi:10.1159/000529574 · Cited by 158
Metadata
- Authors
- Carmeliet, P., & Jain, R. K.
- Affiliations
- Vlaams Instituut voor Biotechnologie (BE)
- Harvard University (US)
- ORCID
- Carmeliet, Peter
- Venue
- Nature
- Published
- 2000-09
- Volume
- 407
- Issue
- 6801
- Pages
- 249-257
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1573363574
- Cited by
- 9,070
- References
- 72
- Citations by year
- 2026: 166 · 2025: 208 · 2024: 246 · 2023: 330 · 2022: 335 · 2021: 381 · 2020: 368 · 2019: 349 · 2018: 375 · 2017: 380 · 2016: 378 · 2015: 364 · 2014: 414 · 2013: 412 · 2012: 416
- FWCI
- 19.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- pathological angiogenesis, cancer, ischemic diseases, inflammatory diseases, anti-angiogenic therapy, clinical trials
- MeSH terms
- Animals, Disease, Humans, Lymphokines, Neoplasms, Neovascularization, Pathologic, Endothelial Growth Factors, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.